Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) Stock
Fundamentals
Source: third-party data provider, as of October 13, 2026
Compare with KNSA
Recent news

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
KNSA

Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
KNSA

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
KNSA

Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
KNSA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 58.81
- MACD 12/26/9
- 0.50
- EMA 9 of MACD
- 0.14
- MACD histogram
- 0.35
- SMA 50
- $77.60
- Price above SMA 50
- EMA 50
- $75.24
- Price above EMA 50
- SMA 200
- $57.29
- Price above SMA 200
- EMA 200
- $59.66
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 12, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
KNSA

Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
KNSA

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
KNSA

Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
KNSA

Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights
KNSA

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates
KNSA

5 Stocks With Recent Price Strength Despite Recent Market Volatility
5 Stocks With Recent Price Strength Despite Recent Market Volatility
KNSA

Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why
Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why
KNSA

4 Top-Ranked Stocks With Solid Net Profit Margins to Boost Your Gains
4 Top-Ranked Stocks With Solid Net Profit Margins to Boost Your Gains
KNSA

Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why
Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why
KNSA
News tone: automated (AI) classification of the article's content, not a price prediction.
About Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Sanjiv K. Patel | CEO & Chairman of the Board | 1969 |
| Mr. Mark A. Ragosa C.F.A. | Executive VP & CFO | 1974 |
| Mr. Ross Michael Moat | Executive VP, COO & Principal Operating Officer | 1980 |
| Dr. John F. Paolini FACC, M.D., Ph.D. | Executive VP & Chief Medical Officer | 1965 |
| Mr. Eben Tessari | Consultant | 1982 |
| Mr. Michael R. Megna CPA | Senior VP & Chief Accounting Officer | 1971 |
| Ms. Mei Jang | Senior VP & Chief Technical Officer | — |
| Mr. Jonathan Kirshenbaum | Investor Relations Officer | — |
| Mr. Douglas J. Barry | Senior VP, Chief Legal Officer & Secretary | — |
| Ms. Martina Struck Ph.D. | Senior VP & Chief Regulatory Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 13, 2026
Technical indicators
- RSI 14
- 58.81
- MACD 12/26/9
- 0.50
- EMA 9 of MACD
- 0.14
- MACD histogram
- 0.35
- SMA 50
- $77.60
- Price above SMA 50
- EMA 50
- $75.24
- Price above EMA 50
- SMA 200
- $57.29
- Price above SMA 200
- EMA 200
- $59.66
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 12, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $90.00
- Average
- $98.80
- High
- $107.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -9.4 | -8.7 | +4.2 | |||||||||
| 2022 | -9.2 | -10.5 | -4.3 | -13.2 | -18.6 | +27.5 | -2.1 | +20.1 | +7.3 | -15.0 | +31.5 | -12.1 |
| 2023 | +0.1 | -11.4 | -14.4 | -2.0 | +26.2 | -0.6 | +35.0 | -8.8 | -2.2 | -9.8 | +6.8 | +4.3 |
| 2024 | -4.9 | +16.1 | -9.2 | -5.0 | -2.0 | -5.3 | +47.8 | +3.8 | -3.9 | -11.3 | -1.8 | -9.5 |
| 2025 | -1.7 | +7.4 | +3.5 | +23.9 | -1.4 | -0.9 | +11.1 | +4.7 | +13.3 | -4.2 | +13.5 | +0.8 |
| 2026 | +4.5 | -0.4 | +4.7 | +11.7 | -12.5 | +32.0 | +18.2 | +7.1 | -5.9 | +5.3 |



